NasdaqGM:KYMRBiotechs
A Look At Kymera Therapeutics (KYMR) Valuation After Late Breaking KT-621 AAD 2026 Selection
Kymera Therapeutics (KYMR) is back in focus after announcing that Phase 1b data for its oral STAT6 degrader KT-621 will appear in a late-breaking oral session at the 2026 American Academy of Dermatology meeting.
See our latest analysis for Kymera Therapeutics.
At a share price of US$77.91, Kymera’s 1 year total shareholder return of 139.43% and 3 year total shareholder return of 165.63% point to strong momentum, even with a 10.86% 1 month share price decline and recent profit taking by...